BMO Capital Markets Boosts UnitedHealth Group (UNH) Price Target to $275.00

UnitedHealth Group (NYSE:UNH) had its price objective lifted by BMO Capital Markets from $14.50 to $275.00 in a report published on Wednesday. BMO Capital Markets currently has an outperform rating on the healthcare conglomerate’s stock.

Several other research firms have also recently commented on UNH. Piper Jaffray Companies reissued a buy rating and set a $259.00 target price on shares of UnitedHealth Group in a research report on Wednesday. Royal Bank of Canada lifted their target price on shares of UnitedHealth Group from $269.00 to $280.00 and gave the stock an outperform rating in a research report on Wednesday. Cantor Fitzgerald reissued a buy rating and set a $235.00 target price on shares of UnitedHealth Group in a research report on Tuesday. Jefferies Group reissued a buy rating and set a $248.00 target price on shares of UnitedHealth Group in a research report on Friday, December 1st. Finally, Leerink Swann reissued an outperform rating on shares of UnitedHealth Group in a research report on Friday, December 1st. Three equities research analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $241.30.

UnitedHealth Group (NYSE:UNH) opened at $243.35 on Wednesday. UnitedHealth Group has a 1 year low of $156.49 and a 1 year high of $244.35. The firm has a market cap of $235,290.00, a PE ratio of 22.72, a P/E/G ratio of 1.42 and a beta of 0.66. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.73 and a quick ratio of 0.70.

UnitedHealth Group (NYSE:UNH) last announced its quarterly earnings results on Tuesday, January 16th. The healthcare conglomerate reported $2.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.50 by $0.09. UnitedHealth Group had a net margin of 5.25% and a return on equity of 21.29%. The business had revenue of $52.06 billion for the quarter, compared to analysts’ expectations of $51.57 billion. During the same quarter last year, the firm earned $2.11 EPS. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. equities analysts expect that UnitedHealth Group will post 12.53 earnings per share for the current year.

In other news, Director Gail R. Wilensky sold 5,600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $223.31, for a total transaction of $1,250,536.00. Following the completion of the sale, the director now owns 61,137 shares in the company, valued at approximately $13,652,503.47. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kenneth Irwin Shine sold 457 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $211.03, for a total transaction of $96,440.71. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,655 shares of company stock valued at $7,469,083. 0.89% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of the company. Blue Chip Partners Inc. purchased a new position in UnitedHealth Group in the 2nd quarter valued at approximately $110,000. Bruderman Asset Management LLC purchased a new position in UnitedHealth Group in the 2nd quarter valued at approximately $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in UnitedHealth Group by 433.3% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 640 shares of the healthcare conglomerate’s stock valued at $119,000 after buying an additional 520 shares in the last quarter. BDO Wealth Advisors LLC purchased a new position in UnitedHealth Group in the 2nd quarter valued at approximately $121,000. Finally, Acrospire Investment Management LLC grew its stake in UnitedHealth Group by 130.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 706 shares of the healthcare conglomerate’s stock valued at $131,000 after buying an additional 400 shares in the last quarter. Institutional investors own 86.09% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/20/bmo-capital-markets-boosts-unitedhealth-group-unh-price-target-to-275-00.html.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.

Analyst Recommendations for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply